SCHEMBL200998

SCHEMBL200998

CCCc1ccc(-c2ccc(C(=O)NC(C(=O)NO)C(F)(F)F)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.48
POLB P06746 3/20 0.47
CTDSP1 Q9GZU7 3/20 0.47
TAS1R3 Q7RTX0 2/20 0.45
TAS1R1 Q7RTX1 2/20 0.45
ANPEP P15144 1/20 0.44
GAA P10253 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CTSS P25774 1/20 0.40
KMT2A Q03164 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
RARB P10826 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12361495 0.88 PLK1 (0.48) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL202434 0.85 TAS1R3 (0.57) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL13267176 0.82 PLK1 (0.50) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL201274 0.81 TAS1R3 (0.52) PLK1TAS1R3TAS1R1ANPEPGAA
SCHEMBL201374 0.81 ANPEP (0.54) ANPEPALDH1A1MMP2NPC1
SCHEMBL201342 0.81 TAS1R3 (0.55) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL404117 0.80 TAS1R3 (0.56) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL399540 0.79 TAS1R3 (0.49) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL5453119 0.79 TAS1R3 (0.49) PLK1POLBCTDSP1TAS1R3TAS1R1
SCHEMBL401475 0.79 TAS1R3 (0.55) PLK1POLBCTDSP1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 PLK1 4226/4885POLB 1478/4885CTDSP1 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.